Recombinant HRP Anti-BRMS1 antibody [EPR7202] (ab208862)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- HRP Rabbit monoclonal [EPR7202] to BRMS1
- Suitable for: WB
- Reacts with: Human
- Conjugation: HRP
Related conjugates and formulations
Overview
-
Product name
HRP Anti-BRMS1 antibody [EPR7202]
See all BRMS1 primary antibodies -
Description
HRP Rabbit monoclonal [EPR7202] to BRMS1 -
Host species
Rabbit -
Conjugation
HRP -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: HeLa whole cell lysate.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. Store In the Dark. -
Storage buffer
pH: 7.40
Preservative: 0.1% Proclin 300 Solution
Constituents: PBS, 1% BSA, 30% Glycerol (glycerin, glycerine) -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR7202 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Positive Controls
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab208862 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/5000. Detects a band of approximately 33 kDa (predicted molecular weight: 28 kDa).
|
Notes |
---|
WB
1/5000. Detects a band of approximately 33 kDa (predicted molecular weight: 28 kDa). |
Target
-
Function
Transcriptional repressor. Down-regulates transcription activation by NF-kappa-B by promoting the deacetylation of RELA at 'Lys-310'. Promotes HDAC1 binding to promoter regions. Down-regulates expression of anti-apoptotic genes that are controlled by NF-kappa-B. Promotes apoptosis in cells that have inadequate adherence to a substrate, a process called anoikis, and may thereby inhibit metastasis. May be a mediator of metastasis suppression in breast carcinoma. -
Tissue specificity
Expression levels are higher in term placentas than in early placentas. Low levels of expression observed in normal pregnancies and in molar pregnancies. -
Sequence similarities
Belongs to the BRMS1 family. -
Cellular localization
Nucleus. Cytoplasm. Predominantly nuclear. - Information by UniProt
-
Database links
- Entrez Gene: 25855 Human
- Omim: 606259 Human
- SwissProt: Q9HCU9 Human
- Unigene: 100426 Human
-
Alternative names
- AV003220 antibody
- AW554636 antibody
- Breast cancer metastasis suppressor 1 antibody
see all
Images
-
HRP Anti-BRMS1 antibody [EPR7202] (ab208862) at 1/5000 dilution +
HeLa whole cell lysate (ab150035) at 10 µg
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 28 kDa
Observed band size: 33 kDa why is the actual band size different from the predicted?
Exposure time: 20 minutesThis blot was produced using a 4-12% Bis-tris gel under the MES buffer system. The gel was run at 200V for 35 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab208862 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab208862 has not yet been referenced specifically in any publications.